Année d’arrivée au Centre
1992
Formation
- Docteur en Médecine Université Catholique de Louvain (B) Spécialité Médecine Interne/Hélmatologie
Interventions pratiquées ou expertise
- Syndrome Myélodysplasique (GFM)
- Lymphome Hodgkinien (LYSA)
Sociétés savantes
- GFM
- SFH
- SFGM
- LYSA
Publications majeures
- Daily practice management of myelodysplastic syndromes in France: data from 907 patients in a one-week cross-sectional study by the Groupe Francophone des Myelodysplasies.
Haematologica. 2010 Jun;95(6):892-9. - Development of a multiplex PCR assay for the detection of genomic copy number changes in myelodysplastic syndromes.
Leuk Res. 2012 May;36(5):e93-7 - Clinical experience of bendamustine in relapsed or refractory Hodgkin lymphoma: a retrospective analysis of the French compassionate use program in 28 patients.
Leuk Lymphoma. 2013 Nov;54(11):2399-404. - Hypoalbuminemia and hypergammaglobulinemia are associated with an increased infection risk in patients with myeloid malignancies treated with azacitidine. A 3-year monocentric retrospective study.
Leuk Lymphoma. 2016;57(6):1491-3 - Detection and prognostic value of recurrent exportin 1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin lymphoma.
Haematologica. 2016 Sep;101(9):1094-101. - Autologous stem cell transplantation for patients aged 60 years or older with refractory or relapsed classical Hodgkin’s lymphoma: a retrospective analysis from the French Society of Bone Marrow Transplantation and Cell Therapies (SFGM-TC).
Bone Marrow Transplant. 2016 Jul;51(7):928-32. - Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial.
Lancet Haematol. 2018 Feb;5(2):e63-e72. - Patient and physician preferences for first-line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom.
Br J Haematol. 2019 Jan;184(2):202-214. - PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study.
Lancet Oncol. 2019 Feb;20(2):202-215. - Performance of CT Compared with 18F-FDG PET in Predicting the Efficacy of Nivolumab in Relapsed or Refractory Hodgkin Lymphoma.
Radiology. 2020 Apr 14:192056.